SRSF2 and myelodysplastic syndrome: Surprisingly, unlike solid tumors, RNA-sequencing data from CD34+ cells of patients with MDS exhibited no significant difference in the inclusion of SR protein poison exons in SRSF2 mutated samples compared to wild-type (WT) samples [9].